Physician profile
Georges Tanbe
NPI 1679733646
$16,638.66
in general payments reported to CMS, 2019-2025
33 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,473 · 2020: $3,752 · 2021: $1,482 · 2022: $1,533 · 2023: $1,828 · 2024: $1,480 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,359 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,358.58 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $4,840.00 | 2019-2020 | |
| Penumbra, INC. | $1,722.10 | 2019 | |
| Abbott Laboratories | $1,632.40 | 2020-2025 | Aveir, Jot Dx, Merlin@Home |
| Novartis Pharmaceuticals Corporation | $1,050.97 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $952.38 | 2019-2025 | Lifevest |
| Pfizer INC. | $717.83 | 2022-2025 | |
| Abiomed | $623.45 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $612.13 | 2019-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $541.33 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $527.71 | 2019-2025 | Farxiga, Andexxa, Brilinta |
| Boston Scientific Corporation | $367.73 | 2019-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.62 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $341.41 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $308.14 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $262.66 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $248.40 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $214.94 | 2021-2024 | Xarelto |
| Medtronic, INC. | $185.37 | 2021-2025 | Mycarelink, Reveal Linq, Micra |
| Philips North America LLC | $166.03 | 2019 | |
| Cardiovascular Systems INC. | $158.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.35 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $124.64 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $93.11 | 2024 | Arcalyst |
| Cleerly, INC. | $77.83 | 2025 | Cleerly Labs |
| Novo Nordisk INC | $73.42 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $67.41 | 2019-2025 | Evkeeza |
| Amarin Pharma, INC. | $57.08 | 2021-2023 | |
| Infobionic, INC | $55.46 | 2023 | Mome Kardia |
| Acist Medical Systems, INC. | $38.96 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.85 | 2025 | Amvuttra |
| Lilly USA, LLC | $22.85 | 2025 | Mounjaro, Zepbound |
| Cvrx, INC. | $17.17 | 2023 | Barostim Neo System |
| Irhythm Technologies, INC. | $15.55 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Tanbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.